MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at the 8
Annual JMP Securities Healthcare Conference on Wednesday, July 10, 2013 at 11:00 AM (ET) at The St. Regis Hotel in New York.
Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product candidate, AFREZZA®, is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MannKind maintains a website at
to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.